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Abstract 
Background: Recently the 8th version of the American Joint Committee on Cancer (AJCC) classification has been 
introduced, and has attempted to define a more accurate and precise definition of prognosis in line with the major 
progresses in understanding the biology and pathogenesis of melanoma. This new staging system introduces major 
changes in the stage III staging system. Indeed, surgical practice is changing in stage III patients, since, according to 
recent evidence, there is no survival benefit in radical lymph node dissection following a positive sentinel lymph node 
dissection. Therefore, some patients currently staged IIIB-C after dissection could be downgraded to IIIA (as in the case 
of patients with metastatic non-sentinel lymph nodes) since many completion lymph node dissections will no longer 
be performed. Moreover, new and effective targeted and immune strategies are being introduced in the pharmaco-
logical armamentarium in the adjuvant setting, showing major efficacy.
Conclusions: This article provides the authors’ personal view on the above-mentioned topics.
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Background
The American Joint Committee on Cancer (AJCC) classi-
fication has represented the reference staging system for 
melanoma for many decades. Recently, the AJCC 8th ver-
sion has been introduced, and it has attempted to define 
a more accurate and precise definition of prognosis in 
line with the major progresses in understanding the biol-
ogy and pathogenesis of melanoma [1].
However, this new staging system has been largely 
criticized [2]. For instance, it uses the same histological 
factors of the AJCC 7th version, and although with some 
refinements, it does not introduce any new prognos-
tic biomarkers; moreover, in stages I–III melanoma, the 
AJCC 8th version is still based on 5- and 10-year mela-
noma-specific survival, and does not take into account 
the increased survival in stage IV melanoma associated 
with the introduction of new therapies. Even more 
importantly, the AJCC 8th version introduces major 
changes in the stage III staging system [2]. Indeed, sur-
gical practice is changing in stage III patients, since two 
studies have shown that there is no survival benefit in 
radical lymph node dissection after a positive sentinel 
lymph node dissection [3, 4]. Therefore, some patients 
currently staged IIIB–C after dissection could be down-
graded to IIIA (as in the case of patients with metastatic 
non-sentinel lymph nodes) since many completion lymph 
node dissections (CLND) will no longer be performed. 
Moreover, new and effective targeted and immune 
strategies are being introduced in the pharmacological 
armamentarium in the adjuvant setting, showing major 
efficacy [5–7]. Other trials are ongoing (Table  1), and 
others will start, likely leading to complete changes in the 
therapeutic approach for stage III melanoma.
This article provides the authors’ personal view on the 
above-mentioned topics.
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Complete dissection or observation for patients 
with sentinel node metastasis
In a recent landmark international trial, Faries et al. ran-
domly assigned patients with sentinel node metastases 
to lymph node dissection (dissection group; n = 824) or 
nodal observation with ultrasonography (observation 
group; n = 931) [4]. Patients in the dissection group did 
not show improved melanoma-specific survival com-
pared with those in the observation group (86 ± 1.3% vs 
86 ± 1.2%) at a median follow-up of 43  months (Fig.  1) 
[4]. However, the rate of disease-free survival was slightly 
higher in the dissection group (68 ± 1.7% vs 63 ± 1.7%; 
p = 0.05), given an increased rate of disease control in 
the regional nodes at 3  years (92 ± 1.0% vs 77 ± 1.5%; 
p < 0.001). Statistical analysis revealed that non-sentinel 
node metastases (reported in 11.5% of the patients in the 
dissection group) represent an independent prognostic 
factor for recurrence (hazard ratio [HR]: 1.78; p = 0.005). 
Overall, these findings demonstrate that immediate com-
pletion of lymph node dissection can increase the rate of 
regional disease control and provide prognostic informa-
tion, without actually improving melanoma-specific sur-
vival. However, the patients in this study were a highly 
selected group with an extremely low burden of sentinel 
node disease (median tumor burden < 1 mm and only one 
node involved in 70% of patients). Similar results were 
reported in another pivotal multicenter, phase III trial 
by Leiter et al. [3]. In this latter study, which was termi-
nated early due to difficulties in enrollment and low event 
rate, patients were randomly assigned to either CLND 
(n = 243) or observation (n = 233) [3]. Distant metasta-
sis-free survival at 3 years was 74.9% (90% CI 69.5–80.3) 
following CLND and 77.0% (90% CI 71.9–82.1) in the 
observation group, similarly no differences in overall sur-
vival (OS) were found between the two groups.
According to the above-mentioned bases, there 
appears to be no survival benefit associated with CLND, 
although this strategy can lead to more refined staging 
and regional node control. For instance, a recent ret-
rospective study from the European Organisation for 
Research and Treatment of Cancer (EORTC), including 
1015 patients, showed that CLND led to upstaging in 
N-category in 19% and in AJCC stage in 5–6% [8]. Simi-
lar findings were reported by Madu et al. [9].
Active surveillance for patients who do not undergo 
CLND following a positive sentinel lymph node should 
include nodal ultrasound as a component of the follow-
up strategy. CLND should be discussed with patients 
clarifying the risks, benefits and alternatives of the proce-
dure, including their overall risk of harboring metastatic 
non-sentinel lymph nodes and the impact of dissection 
on staging, regional control and survival. In this regard, 
the Italian Melanoma Intergroup has developed a nomo-
gram to predict the risk of non-sentinel node positivity, 
which can help clinicians to discuss with patients the 
opportunity of CLND [10].
However, with the advent of the new adjuvant treat-
ments, there is probably less need for indicating a CLND.
The importance of adjuvant therapy
In light of the evolving landscape of adjuvant therapy 
in melanoma and the lack of survival benefit of CLND, 
it becomes important to explore possible consequences 
of omitting CLND, and whether it is possible to stratify 
positive sentinel node patients on the basis of infor-
mation retrieved from sentinel lymph node biopsy 
[8]. Verver et  al. in a retrospective analysis from nine 
Table 1 Ongoing major trials in stage III melanoma
Trial name Trial ID Aim
Checkmate 915 NCT03068455 To determine whether nivolumab + ipilimumab, is more effective than nivolumab alone, in delaying recurrence in 
patients with complete surgical removal of stage IIIb/c/d or stage IV melanoma
ECOG 1619 NCT01274338 To compare adjuvant ipilimumab with high-dose interferon alfa-2b in treating patients with high-risk stage III–IV 
melanoma that has been removed by surgery
SWOG S1414 [27] MCT02506153 Randomized trial comparing standard of care to pembrolizumab in patients at high risk for recurrence and death 
after surgery
Fig. 1 Melanoma-specific survival following completion lymph-node 
dissection or observation in the per-protocol analysis of the trial by 
Faries et al. [4]. Reproduced with permission
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EORTC melanoma group centers, showed that ade-
quate stratification of patients with sentinel lymph 
nodes was possible based on ulceration and tumor 
burden category, with 1  mm being the threshold to 
distinguish between low-/intermediate- and high-risk 
patients [8]. In particular, the identification of low-, 
intermediate- and high-risk patients could help select 
adjuvant therapy in clinical practice.
To this end, the therapeutic efficacy of adjuvant treat-
ment with IFN-α for the treatment of patients with 
AJCC stage II–III cutaneous melanoma in terms of 
both disease-free survival and, to a lower extent, OS 
was already shown in two pivotal meta-analyses [11, 
12]. More recently, a number of studies have investi-
gated adjuvant therapy with newly introduced treat-
ments, and therefore since 2011 the treatment of 
advanced or metastatic melanoma has undergone a 
sort of revolution with the introduction, which has 
also been recently evaluated in an adjuvant setting in a 
number of randomized clinical trials (Table 2) [13].
Vemurafenib
The phase III, international, double-blind, randomized, 
placebo-controlled BRIM8 trial evaluated adjuvant 
vemurafenib monotherapy in melanoma [14]. In total, 
498 patients with histologically confirmed stage IIC–
IIIA–IIIB or stage IIIC BRAFV600 mutation-positive 
melanoma that had been fully resected were randomly 
assigned to either twice-daily adjuvant oral vemurafenib 
or placebo for 52  weeks. The primary endpoint was 
disease-free survival, which was evaluated separately 
in each cohort. Median follow-up was 33.5  months in 
patients with stage IIIC and 30.8 months in those with 
stage IIC–IIIA–IIIB disease. In the former cohort, 
median disease-free survival was 23.1 months (95% CI 
18.6–26.5) with vemurafenib and 15.4 months (95% CI 
11.1–35.9) with placebo (HR: 0.80, 95% CI 0.54–1.18; 
p = 0.26). In the latter cohort (patients with stage IIC–
IIIA–IIIB disease), median disease-free survival was 
not reached in the vemurafenib group compared with 
36.9  months (95% CI 21.4–not estimable) in the pla-
cebo group (HR: 0.54; 95% CI 0.37–0.78; p = 0.0010); 
however, statistical significance was not reached 
because of the prespecified hierarchical prerequisite for 
the primary disease-free survival analysis. Moreover, 
the particular trend of the disease-free survival curve 
in the vemurafenib group, which shows an increase in 
the incidence of relapse after some time on treatment, 
does suggest that BRAF inhibitors alone may not be 
sufficient to prevent relapse. These findings suggest that 
adjuvant vemurafenib may not be considered an opti-
mal treatment regimen in this patient population.
Dabrafenib + trametinib
In the randomized COMBI-AD phase III trial, 
patients with resected BRAFV600-mutant stage III 
melanoma (IIIA with deposits more than 1  mm, 
IIIB–IIIC) were assigned to 12  months’ adjuvant dab-
rafenib + trametinib or placebo [6, 15]. At a median 
follow-up of 2.8  years, the estimated 3-year rate of 
relapse-free survival (RFS) was 58% with the combina-
tion therapy versus 39% with placebo group (HR: 0.47, 
95% CI 0.39–0.58; p < 0.001). The 3-year OS rates were 
86% and 77%, respectively (HR: 0.57, 95% CI 0.42–0.79; 
p = 0.0006), but this level of improvement did not cross 
the prespecified interim analysis boundary to claim sta-
tistical significance (based on a prespecified threshold 
of p = 0.000019). Rates of distant metastasis-free sur-
vival and freedom from relapse were also higher with 
dabrafenib + trametinib compared with placebo.
At the updated analysis of the COMBI-AD trial, with 
a median follow-up of 44 (dabrafenib + trametinib) or 
42 months (placebo), 3- and 4-year RFS rates were 59% 
(95% CI 55–64%) and 54% (95% CI 49–59%) with dab-
rafenib + trametinib, and 40% (95% CI 35–45%) and 38% 
(95% CI 34–44%) with placebo, respectively (HR: 0.49, 
95% CI 0.40–0.59) [15]. Similarly, distant metastasis-free 
survival was longer with dabrafenib + trametinib (HR: 
0.53, 95% CI 0.42–0.67). The estimated cure rate was 
54% (95% CI 49–59%) in the dabrafenib + trametinib arm 
compared with 37% (95% CI 32–42%) in the placebo arm. 
Subgroup analysis showed that dabrafenib + trametinib 
benefited patients regardless of different baseline factors, 
including disease stage, nodal metastatic burden and 
ulceration.
At the American Society of Clinical Oncology (ASCO) 
2018 meeting, the patients included in the COMBI-AD 
trial were re-staged according to the new AJCC 8th edi-
tion system. The benefit of dabrafenib + trametinib 
was observed across all AJCC 8th edition subgroups in 
resected high-risk stage III melanoma patients, even if it 
was less evident and not reaching statistical significance 
for stage IIIA.
A biomarker analysis of the COMBI-AD trial was 
recently presented. MAPK pathway gene alterations did 
not correlate with outcomes, while immune gene-expres-
sion signatures (e.g., IFN-γ) were strongly prognos-
tic in both arms. High tumor mutational burden added 
positive prognostic value to IFN-γ signature in the pla-
cebo arm, whereas in the combination arm, it identified 
patients with longer RFS independently of tumor muta-
tional burden. Remarkably, at this analysis, the rate of 
loco-regional recurrence (without distant involvement) 
with dabrafenib + trametinib was 32% compared with 
43% with placebo. Rates of distant-only recurrences were 
59% and 51%, respectively.
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Ipilimumab
Eggermont et  al. conducted a phase III trial to evalu-
ate adjuvant ipilimumab (10  mg/kg) in patients with 
complete resection of stage III melanoma [16]. Patients 
were randomly assigned to ipilimumab (n = 475) or pla-
cebo (n = 476) for up to 3 years or until disease recur-
rence or an unacceptable level of toxic effects occurred. 
At a median follow-up of 5.3  years, the 5-year rate of 
RFS (primary endpoint) was 40.8% with ipilimumab 
and 30.3% with placebo group (HR: 0.76, 95% CI 
0.64–0.89; p < 0.001). At 5  years, the rates of OS were 
65.4% and 54.4%, respectively (HR: 0.72, 95.1% CI 
0.58–0.88; p = 0.001), and the rates of distant metas-
tasis-free survival were 48.3% and 38.9%, respectively 
(HR: 0.76, 95.8% CI 0.64–0.92; p = 0.002). Grade 3–4 
adverse events were reported in 54.1% of the patients 
on ipilimumab group and in 26.2% of those assigned 
to placebo; grade 3–4 immune-related adverse events 
occurred in 41.6% of patients (fatal in five cases, 1.1%) 
on ipilimumab group versus 2.7% of those taking pla-
cebo. The authors concluded that ipilimumab may rep-
resent an effective adjuvant therapy for high-risk stage 
III melanoma, although the high rates of immune-
related adverse events with ipilimumab can represent a 
concern.
Nivolumab
In a randomized, double-blind, phase III trial, Weber 
et  al. evaluated the efficacy of nivolumab compared 
with ipilimumab, for adjuvant therapy in patients with 
resected advanced melanoma [5]. In total, 906 patients 
undergoing complete resection of stage IIIB, IIIC or IV 
melanoma were assigned to either nivolumab (3  mg/
kg every 2  weeks) or ipilimumab (10  mg/kg every 
3  weeks for four doses and then every 12  weeks), for 
a maximum period of 1 year. In the presence of recur-
rence, patients could cross-over to pembrolizumab if 
randomized in the placebo arm or repeat pembroli-
zumab (recurrence more than 6  months after the end 
of treatment). At a minimum follow-up of 18  months, 
the 12-month rate of RFS higher with nivolumab than 
with ipilimumab (70.5% [95% CI 66.1–74.0] vs 60.8% 
[95% CI 56.0–65.2]; HR: 0.65, 97.56% CI 0.51–0.83; 
p < 0.001). Grade 3–4 treatment-related adverse events 
were reported in 14.4% of the patients on nivolumab 
and 45.9% of those on ipilimumab group, with a lower 
discontinuation rate for adverse events with nivolumab 
(9.7% vs 42.6%). These data showed that adjuvant ther-
apy with nivolumab among patients undergoing resec-
tion of stage IIIB, IIIC or IV melanoma can result in 
longer RFS and a lower rate of grade 3–4 adverse events 
compared with adjuvant ipilimumab.
Pembrolizumab
Adjuvant therapy with pembrolizumab in patients 
with resected, high-risk stage III melanoma was evalu-
ated in the recently published phase III, double-blind 
KEYNOTE-054 trial (EORTC 1325) [7]. Patients were 
randomly assigned to either pembrolizumab (n = 514) 
or placebo (n = 505) for a maximum period of approxi-
mately 1  year. At a median follow-up of 15  months, 
patients on pembrolizumab showed a higher 1-year 
rate of RFS than placebo (75.4% [95% CI 71.3–78.9] vs 
61.0% [95% CI 56.5–65.1; HR: 0.57, 98.4% CI 0.43–0.74; 
p < 0.001). This finding was consistent in the 853 patients 
with PD-L1-positive tumors (77.1% vs 62.6%; HR: 0.54, 
95% CI 0.42–0.69; p < 0.001). Grade 3–5 treatment-
related adverse events were reported in 14.7% of patients 
in the pembrolizumab group and in 3.4% of patients in 
the placebo group. One treatment-related death (myosi-
tis) occurred in the pembrolizumab group.
At the Society for Melanoma Research (SMR) 2018 
meeting, the prognostic and predictive value of AJCC-8 
staging in the KEYNOTE-054 trial of pembrolizumab 
were presented [17]. Remarkably, the application of the 
AJCC-8 classification allowed to identify subgroups with 
different 1-year rate of RFS (stage IIIA [8% of the total 
number of patients]: 92.6%; stage IIID [4%]: 42.1%), and 
therefore AJCC-8 stage appears to be a strong prognos-
tic factor. However, the benefit of pembrolizumab was 
observed across all AJCC-8 subgroups in resected high-
risk stage III melanoma patients, thus suggesting that 
sub-staging retains no predictive importance when adju-
vant therapy is administered.
Implications for clinical practice
The new therapies introduced for stage IV melanoma do 
retain their efficacy also in the adjuvant setting: indeed, 
the best performers in stage IV are best performers in the 
adjuvant setting. In particular, recent developments in 
immunotherapy have prolonged OS in metastatic mela-
noma with the possibility to reach a long-term benefit 
[18]. Targeted therapies based on the combined BRAF 
and MEK inhibition also exert a long-term beneficial 
effect, which is more evident in patients with favorable 
baseline characteristics, namely normal levels of lactate 
dehydrogenase, with no brain metastases, and low tumor 
burden while elevated LDH, high tumor burden and 
brain metastasis should be considered as negative predic-
tive factors [18]. This long-term benefit of targeted thera-
pies may be related to an immune modulation: indeed, 
BRAF and MEK inhibitors affect tumor microenviron-
ment and immune surveillance, and patients with com-
plete response to targeted treatment have a pre-existing 
favorable immunologic signature [18].
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What can we learn from the recent trials on surgery 
for stage III melanoma and trials in the adjuvant set-
ting? Perhaps, the most relevant finding with immediate 
relevance to clinical practice comes from the Combi-AD 
update, presented by Georgina Long at the latest ESMO 
meeting. From these results it clearly stems that, at least 
for target therapy, adjuvant treatment prevents mainly 
loco-regional recurrence (− 11% with respect to placebo). 
Therefore, although in other recent adjuvant studies the 
enrolled patients underwent to an elective lymph nodes 
dissection before treatment, we believe that surgery 
could be postponed in case of loco-regional recurrence, 
and not performed immediately after sentinel node 
biopsy. This suggestion is supported by the results of the 
MSLT-II trial, which showed no impact of lymphadenec-
tomy on melanoma-specific survival [4]. Of course, this 
applies only in case of micrometastases, as discovered 
by histology; in case of clinical overt recurrence, elective 
lymph node dissection should still be considered the first 
option. Moreover, patients eligible to adjuvant treatment 
in real life are markedly different from those included in 
clinical trials, as they are classified according to the new 
AJCC 8th classification instead of AJCC 7th classifica-
tion, and also because the majority of patients in clinical 
practice would not have undergone CLND.
While for stage IIIB, C and D is well recognized the role 
of adjuvant, the role of this strategy in stage IIIA is more 
debated. Indeed, according to recent evidence we feel 
that in these patients the tumor burden within metastatic 
sentinel nodes should drive the decision on addressing 
or not them to the adjuvant treatment. In particular, a 
tumor burden of the sentinel nodes metastases > 1  mm 
allows to identify a high-risk patient, eligible to adjuvant 
treatment, as first suggested by van Akkooiin a land-
mark paper published in 2008 (Fig.  2) [10, 19]. On the 
other hand, in case of IIIA disease with a sentinel node 
metastasis < 1  mm, adjuvant should not be considered, 
since the risk of side effects—which can be also perma-
nent in case of immunotherapy—is too high given the 
ultimate expected prognosis. Remarkably, most trials on 
stage IIIA enroll patients with sentinel nodes metastases 
> 1 mm. Overall, we suggest that T1a/T1b/T2a and N1a/
N2a can be considered as selection criteria for adjuvant 
treatment. Moreover, more extended investigation on 
mutational analysis at stage III (e.g., by next-generation 
sequencing [20, 21]) will likely pave the way to new clas-
sification approaches.
With respect to the selection of the adjuvant therapy, 
at present there are no data that to indicate if it is better 
to use target therapy or immunotherapy as first option 
in the adjuvant setting (although targeted therapies can 
be used in patients with positive BRAF V600 mutation). 
Ongoing trials will likely provide a response about this 
issue.
Last, preliminary evidence had suggested that check-
point inhibitors in the neoadjuvant setting (i.e., patients 
with surgically palpable and resectable lymph nodes 
metastasis) may be superior over adjuvant therapy [22–
25]. In a pilot study, 20 patients with palpable stage III 
melanoma were randomly assigned to ipilimumab and 
nivolumab, as either four courses after surgery (adju-
vant arm) or two courses before surgery and two courses 
postsurgery (neoadjuvant arm) [21]. Neoadjuvant ther-
apy was feasible: all patients underwent surgery at the 
preplanned time point, and pathological response was 
achieved in 7/9 patients. No relapses were reported at the 
Fig. 2 Overall survival in association with different sizes of sentinel lymph node according to Van Akkoi et al. [20]. In their study, conducted in 388 
patients at three major centers within the European Organization of Research and Treatment of Cancer (EORTC) Melanoma Group, estimated overall 
survival at 5 years was 91% for metastasis < 0.1 mm, 61% for 0.1–1.0 mm, and 51% for > 1.0 mm (p < 0.001)
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time of analysis; however, 9/10 patients experienced 3/4 
adverse events. In another study, 8/27 patients on neo-
adjuvant therapy experiences a complete or major patho-
logical response after a single dose of anti-PD-1 therapy, 
and all of them remained disease-free [23]. In another 
randomized, phase II study treatment with combined 
ipilimumab and nivolumab was associated with high 
response rates (overall response rate: 73%, pathological 
complete response:, 45%) but substantial toxicity (73% 
grade III adverse events), while nivolumab monotherapy 
led to modest responses (ORR 25%, pathological com-
plete response: 25%) and low toxicity (8% grade 3 treat-
ment-related adverse events) [24]. Last, a randomized 
phase II trial in 21 patients showed that neoadjuvant plus 
adjuvant dabrafenib and trametinib prolonged event-
free survival versus standard of care (19.7  months vs 
2.9 months) in patients with high-risk, surgically resect-
able, clinical stage III–IV melanoma [25]. Neoadjuvant 
therapy appears to be feasible, although associated with 
a high burden of toxicity and future studies should clar-
ify when this strategy should be preferred over adjuvant 
treatment [26].
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